Search - tctmd.com

Displaying 21 - 37 of 37

Sort: Relevancy | Date

News Daily News

LV Mass Regression After TAVR Linked to Better Long-term Outcomes

Michael O'Riordan

May 13, 2020

News Daily News

Formal Shared Decision-Making Aid for TAVR Gets Mixed Reviews

Michael O'Riordan

January 31, 2020

Presentation TVT 2019

Fix the Valve and Hope for the Best: Can We Do Better?

Presenter: Brian Lindman

June 12, 2019

Presentation The Structural Heart Disease Summit 2018

Keynote Lecture #2: Useful and Evolving Biomarkers in Aortic Stenosis and TAVR - Current Status and Future Directions

Presenter: Brian R Lindman

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Perspectives on the Hierarchy of Valve Centers of Excellence in the US

Presenter: Daniel A Canos, Martin B. Leon, Vinod H. Thourani, Brian R Lindman

June 21, 2018

News Daily News

Sex Differences Diminish With Third-Generation TAVR Device

L.A. McKeown

January 05, 2018

News Daily News

Una Mayor Regresión Precoz de la Masa VI Post-TAVR Reduce las Rehospitalizaciones

June 27, 2014

News Daily News

Greater Early LV Mass Regression After TAVR Reduces Rehospitalization

June 27, 2014

Presentation

Early Regression of Severe LV Hypertrophy After TAVR Is Associated with Decreased Hospitalizations

Presenter: Brian R. Lindman

June 25, 2014

News Daily News

Over the Long Haul, TAVR Appears Better Than Surgery for Women

Caitlin E. Cox

February 19, 2014

News Daily News

A la Larga, la TAVR parece Mejor que la Cirugía en Mujeres

Caitlin E. Cox

February 19, 2014

News Conference News ESC 2013

PARTNER A: TAVR the Optimal Choice for Diabetic Patients at High Risk

Yael L. Maxwell

September 04, 2013

Presentation ESC 2013

Transcatheter versus Surgical Aortic Valve Replacement in Patients with Diabetes and Severe Aortic Stenosis at High Risk for Surgery: PARTNER I, High-risk Cohort

Presenter: Brian R. Lindman

September 03, 2013

Partner Content

Studying the Clinical Impact of Restoring Native Flow with Biomimetic DurAVR® THV

June 6, 2025

CME

Treatment of Severe Aortic Stenosis: Why Wait for Symptoms?

Video

» Interview

Introducing Target AS

June 24, 2024

Video

» Topical Discussion

Medical Therapy in Aortic Valve Disease

January 11, 2024

Advertisement

LV Mass Regression After TAVR Linked to Better Long-term Outcomes

Formal Shared Decision-Making Aid for TAVR Gets Mixed Reviews

Fix the Valve and Hope for the Best: Can We Do Better?

Keynote Lecture #2: Useful and Evolving Biomarkers in Aortic Stenosis and TAVR - Current Status and Future Directions

Perspectives on the Hierarchy of Valve Centers of Excellence in the US

Sex Differences Diminish With Third-Generation TAVR Device

Una Mayor Regresión Precoz de la Masa VI Post-TAVR Reduce las Rehospitalizaciones

Greater Early LV Mass Regression After TAVR Reduces Rehospitalization

Early Regression of Severe LV Hypertrophy After TAVR Is Associated with Decreased Hospitalizations

Over the Long Haul, TAVR Appears Better Than Surgery for Women

A la Larga, la TAVR parece Mejor que la Cirugía en Mujeres

PARTNER A: TAVR the Optimal Choice for Diabetic Patients at High Risk

Transcatheter versus Surgical Aortic Valve Replacement in Patients with Diabetes and Severe Aortic Stenosis at High Risk for Surgery: PARTNER I, High-risk Cohort

Studying the Clinical Impact of Restoring Native Flow with Biomimetic DurAVR® THV

Treatment of Severe Aortic Stenosis: Why Wait for Symptoms?

Introducing Target AS

Medical Therapy in Aortic Valve Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content